EZH2 and cancer: Given the many ongoing clinical trials of EZH2 and EZH1/2 inhibitors in a variety of cancers including HCC38, the combined use of epigenetic therapeutic agents, such as UNC1999, may prove useful to treat patients with advanced HCC.